A part of MilliporeSigma

AB5336P | Anti-Synuclein α Antibody

50 µg  
Retrieving price...
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
Request Pricing
Limited AvailabilityLimited Availability
Limited Quantities Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service

      Special Offers


      Contact Customer Service

      Click To Print This Page


      Replacement Information

      Key Specifications Table

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      H, M, R IH(P) Sh Affinity Purified Polyclonal Antibody
      Catalogue NumberAB5336P
      Brand Family Chemicon®
      Trade Name
      • Chemicon
      DescriptionAnti-Synuclein α Antibody
      Product Information
      FormatAffinity Purified
      PresentationAffinity purified immunoglobulin. Lyophilized. Reconstitute with 50 μL of sterile distilled water. Centrifuge to remove any residue. Glycerol (1:1) can be added for additional stability.
      ApplicationAnti-Synuclein Antibody, α is an antibody against Synuclein for use in IH(P).
      Key Applications
      • Immunohistochemistry (Paraffin)
      Application NotesImmunohistochemistry: 1:1,000 on frozen or paraffin sections.

      Optimal working dilutions must be determined by the end user.
      Biological Information
      ImmunogenSynthetic peptide corresponding amino acids 108-120 of human alpha synuclein.
      SpecificityRecognizes alpha synuclein.
      Species Reactivity
      • Human
      • Mouse
      • Rat
      Antibody TypePolyclonal Antibody
      Entrez Gene Number
      Entrez Gene SummaryAlpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of patients with Alzheimer's disease. Two alternatively spliced transcripts of SNCA have been identified. Additional splicing may be present but the full-length nature of these variants has not been determined.
      Gene Symbol
      • SNCA
      • PD1
      • alpha-synuclein
      • NACP
      • PARK4
      • MGC110988
      • PARK1
      • Alpha-synuclein
      UniProt Number
      UniProt SummaryFUNCTION: SwissProt: P37840 # May be involved in the regulation of dopamine release and transport. Soluble protein, normally localized primarily at the presynaptic region of axons, which can form filamentous aggregates that are the major non amyloid component of intracellular inclusions in several neurodegenerative diseases (synucleinopathies). Induces fibrillization of microtubule- associated protein tau. Reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase 3 activation.
      SIZE: 140 amino acids; 14460 Da
      SUBUNIT: Soluble monomer which can form filamentous aggregates. Interacts with UCHL1 (By similarity). Interacts with phospholipase D and histones.
      SUBCELLULAR LOCATION: Cytoplasm. Membrane. Nucleus. Note=Membrane- bound in dopaminergic neurons. Also found in the nucleus.
      TISSUE SPECIFICITY: Expressed principally in brain but is also expressed in low concentrations in all tissues examined except in liver. Concentrated in presynaptic nerve terminals.
      DOMAIN: SwissProt: P37840 The NAC domain is involved in the fibril formation. The middle region forms the core of the filaments. The C-terminus may regulate aggregation and determine the diameter of the filaments.
      PTM: Phosphorylated, predominantly on serine residues. Phosphorylation by CK1 appears to occur on residues distinct from the residue phosphorylated by other kinases. Phosphorylation of Ser-129 is selective and extensive in synucleinopathy lesions. In vitro, phosphorylation at Ser-129 promoted insoluble fibril formation. Phosphorylated on Tyr-125 by a PTK2B-dependent pathway upon osmotic stress. & Hallmark lesions of neurodegenerative synucleinopathies contain alpha-synuclein that is modified by nitration of tyrosine residues and possibly by dityrosine cross-linking to generated stable oligomers. & Ubiquitinated. The predominant conjugate is the diubiquitinated form (By similarity).
      DISEASE: SwissProt: P37840 # Defects in SNCA are a cause of autosomal dominant Parkinson disease 1 (PARK1) [MIM:168601, 168600]. Parkinson disease (PD) is a complex, multifactorial disorder that typically manifests after the age of 50 years, although early-onset cases (before 50 years) are known. PD generally arises as a sporadic condition but is occasionally inherited as a simple mendelian trait. Although sporadic and familial PD are very similar, inherited forms of the disease usually begin at earlier ages and are associated with atypical clinical features. PD is characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. & Defects in SNCA are the cause of Parkinson disease 4 (PARK4) [MIM:605543, 168600]. & Defects in SNCA are the cause of Lewy body dementia (DLB) [MIM:127750]. DLB is a neurodegenerative disorder clinically characterized by dementia and parkinsonism, often with fluctuating cognitive function, visual hallucinations, falls, syncopal episodes, and sensitivity to neuroleptic medication. Presence of Lewy bodies are the only essential pathologic features. & Deposition of fibrillar amyloid proteins intraneuronally as neurofibrillary tangles is characteristic of Alzheimer disease (AD). SNCA is a minor protein found within these deposits, but a major non amyloid component. & Brain iron accumulation type 1 (NBIA1, also called Hallervorden-Spatz syndrome), a rare neuroaxonal dystrophy, is histologically characterized by axonal spheroids, iron deposition, Lewy body (LB)-like intraneuronal inclusions, glial inclusions and neurofibrillary tangles. SNCA is found in LB-like inclusions, glial inclusions and spheroids.
      SIMILARITY: Belongs to the synuclein family.
      Physicochemical Information
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Storage ConditionsMaintain lyophilized material at -70°C (dry) for up to 12 months. After reconstitution maintain at -20°C in undiluted aliquots for up to 6 months. Avoid repeated freeze/thaw cycles.
      Packaging Information
      Material Size50 µg
      Transport Information
      Supplemental Information




      Safety Data Sheet (SDS) 

      Certificates of Analysis

      TitleLot Number
      SHEEP ANTI-ALPHA SYNUCLEIN -2519334 2519334
      SHEEP ANTI-ALPHA SYNUCLEIN -2716593 2716593
      SHEEP ANTI-ALPHA SYNUCLEIN -2741590 2741590
      SHEEP ANTI-ALPHA SYNUCLEIN -2752719 2752719
      SHEEP ANTI-ALPHA SYNUCLEIN -2804761 2804761
      SHEEP ANTI-ALPHA SYNUCLEIN -2809302 2809302


      Reference overviewPub Med ID
      Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain.
      Eslamboli, A; Romero-Ramos, M; Burger, C; Bjorklund, T; Muzyczka, N; Mandel, RJ; Baker, H; Ridley, RM; Kirik, D
      Brain : a journal of neurology 130 799-815 2007

      Show Abstract
      17303591 17303591
      Aggresome-related biogenesis of Lewy bodies.
      Kevin St P McNaught, P Shashidharan, Daniel P Perl, Peter Jenner, C Warren Olanow
      The European journal of neuroscience 16 2136-48 2002

      Show Abstract
      12473081 12473081
      Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct.
      K A Conway, J C Rochet, R M Bieganski, P T Lansbury
      Science (New York, N.Y.) 294 1346-9 2001

      Show Abstract
      11701929 11701929

      Data Sheet

      Anti-Synuclein, alpha - Data Sheet

      Related Products & Applications

      Related Products

      Catalog Number Description  
      04-1050 Anti-γ-Synuclein Antibody, clone EP1539Y, rabbit monoclonal Show Pricing & Availability
      04-1053 Anti-α-Synuclein (NT) Antibody, clone EP1646Y, rabbit monoclonal Show Pricing & Availability
      36-008 Anti-α-Synuclein Antibody, clone Syn211 Show Pricing & Availability
      36-008-C Anti-alpha-Synuclein (aa 121-125) Antibody, clone Syn211 (Ascites Free) Show Pricing & Availability
      AB5038 Anti-Synuclein α Antibody Show Pricing & Availability
      AB5038P Anti-Synuclein α Antibody Show Pricing & Availability
      AB5334P Anti-Synuclein α Antibody Show Pricing & Availability
      AB9850 Anti-phospho-α Synuclein (Ser129) Antibody Show Pricing & Availability
      MAB5320 Anti-Synuclein α Antibody, clone 7B12.2 Show Pricing & Availability
      MABN389 Anti-Aggregated a-Synuclein Antibody, clone 5G4 Show Pricing & Availability
      MABN633 Anti-a-Synuclein, clone 10D2 Antibody Show Pricing & Availability
      MABN824 Anti-α-syn Antibody (amino acids 115-122), clone LB509 Show Pricing & Availability
      MABN826 Anti-phospho-α-Synuclein (Ser129) Antibody, clone 81A Show Pricing & Availability

      View Gene Related Products for this Target


      Life Science Research > Antibodies and Assays > Primary Antibodies